Sermorelin
Fat LossGHRH(1-29) / discontinued US brandExperimental
GHRH(1–29) formerly marketed as Geref; US brand discontinued (2008). Still compounded. WADA S2 (GHRH analogues).
For research use only.
Key Facts
- CAS
- 86168-78-7
- Molecular Weight (MW)
- 3357.96 g/mol
- Half-life
- ~11-12 minutes
- Unit
- mcg
- Administration Route
- Subcutaneous
- Frequency
- Daily
- Last updated
- 8/23/2026
- Targets
- GHRH receptor
Overview
GHRH(1–29) formerly marketed as Geref; US brand discontinued (2008). Still compounded. WADA S2 (GHRH analogues).
Protocol
- Dosage Range
- 200-300 mcg
- Frequency
- Daily
- Cycle
- 12-16 weeks on, 4-6 off
- Administration Route
- Subcutaneous
- Reconstitution Guide
- 3 mL BAC for 5 mg vial
Science
Mechanism of Action
Native-sequence GHRH fragment that stimulates pituitary GH if the somatotroph axis is intact. Short half-life requires frequent dosing.
Targets
GHRH receptor
Studies
- Sermorelin diagnostic/therapeutic use— Journal/year not available
Benefits
GH-axis diagnostic historyCompounded GHRH analog
Potential Side Effects
- Flushing
- Injection pain
- Taste changes (IV)
References
- PMID 11081149External link · Year —
- WADA Prohibited List 2026External link · Year —